Recent Advances in Drug-Induced Angioedema  by Inomata, Naoko
Allergology International Vol 61, No4, 2012 www.jsaweb.jp 545
Review Series: Advances in Consensus, Pathogenesis and Treatment of Urticaria
and Angioedema
Recent Advances in Drug-Induced
Angioedema
Naoko Inomata1
ABSTRACT
Angioedema is the end result of deep dermal, subcutaneous andor mucosal swelling, and is potentially a life-
threatening condition in cases where the pharynx or larynx is involved. Drug-induced angioedema has been re-
ported to occur in response to a wide range of drugs and vaccines. Drug-induced angioedema, like other cuta-
neous drug reactions, has been reported to be most frequently elicited by beta-lactam antibiotics and non-
steroidal anti-inflammatory drugs, although reliable data from epidemiologic studies are scarce. Recent reports
suggested an increasing role of angiotensin-converting enzyme inhibitors (ACEIs) in the causation of life-
threatening angioedema. ACEI-related angioedema is never accompanied by urticaria and occurs via a kinin-
dependent mechanism. ACEI-related angioedema not only can start years after beginning the treatment, but it
can then recur irregularly while under that treatment. Furthermore, allergy tests are unreliable for the diagnosis
of ACEI-related angioedema, and so the relationship between angioedema and ACEIs is often missed and con-
sequently quite underestimated. Accordingly, better understanding of the kinin-dependent mechanism, which is
particular to angioedema, is necessary for the appropriate management of drug-induced angioedema.
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INTRODUCTION
Angioedema is defined as a deep dermal, subcutane-
ous andor mucous swelling, which usually lasts for 1
to 3 days, whereas urticaria usually represents a
more short-living, superficial dermal swelling due to
plasma leakage and vasodilation.1,2 Angioedema is as-
sociated with various causes and factors, such as
foods, drugs, infection and genetic factors and can be
mediated by different mechanisms.
In recent years, as more drugs become available,
the number of drugs that can induce angioedema has
increased. Drug-induced angioedema has been re-
ported to result from a wide range of drugs and vac-
cines, including non-steroidal anti-inflammatory
drugs (NSAIDs), angiotensin-converting enzyme in-
hibitors (ACEIs), angiotensin II receptor antagonists,
antibiotics, radiocontrast media, proton pump inhibi-
tors, statins, fibrinolytic agents, estrogens, diuretics,
calcium channel blockers, beta blockers, and psy-
chotropic drugs (serotonin reuptake inhibitors).3
Drug-induced angioedema, like other cutaneous drug
reactions, has been reported most frequently elicited
by beta-lactam antibiotics and NSAIDs, although reli-
able data from epidemiologic studies are scarce.4
Drug-induced angioedema is associated with urticaria
in approximately 50% of cases and may be compli-
cated by life-threatening anaphylaxis.4 Although the
combination of urticaria andor angioedema with sys-
temic symptoms like hypotension is typical for IgE-
mediated allergic reactions and aspirin intolerance,
some drugs like ACEIs induced isolated angioedema
by a kinin-dependent mechanism, which is particular
to angioedema but not urticaria. In particular, recent
reports suggest an increasing role of ACEIs in the
causation of angioedema resulting in life-threatening
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Table　1　Comparison of features of angioedema and urticaria
Features Urticaria Angioedema
Pathology
Location Papillary dermal Reticular dermal, subcutaneous/submucosal
Vasodilation +++ +/-
Edema + +++
Cellular infi ltration Sparse perivasucular infi ltrates of mainly neutrophils, 
eosinophils, monocytes and T-lymphocytes
Little or no cellular infi ltrate, except in allergic 
angioedema where eosinophils may be seen
Clinical features
Locaction Skin only Skin and mucosa
Duration Transitory (<24 h) Transitory (24-72 h?)
Color of lesions Red Variable
Skin-colored
Subjective symptoms Itch Pain and heat
Modifi ed from reference 5.
events by upper airway obstruction. Extensive clinical
evaluations of commonly used inhibitors of the renin-
angiotensin system have provided reliable data on the
incidence and clinical manifestations of angioedema
induced by these drugs. Accordingly, current data
have shed new light on bradykinin playing a crucial
role in the pathogenesis of most forms of non-allergic
angioedema without urticaria, while histamine acts as
the main biogenic mediator in allergic angioedema.
Correct diagnosis is indispensable to determine the
appropriate treatment, as standard, anti-allergic
drugs, such as glucocorticoids and antihistamines,
are most likely ineffective in treating non-allergic
forms of angioedema. Unfortunately, angioedema, at
present, seems to be recognized and correctly treated
less than urticaria, although the management of urti-
caria has generally been improved since the guide-
lines for urticarial were proposed. Better understand-
ing of the various forms and underlying mechanisms
of angioedema, including the kinin-dependent mecha-
nism particular to angioedema, is necessary for man-
aging drug-induced angioedema. This review focused
on recent advances in drug-induced angioedema and,
especially, updated NSAID-induced angioedema and
ACEI-related angioedema as representatives of drug-
induced angioedema via a non-allergic mechanism.
ANGIOEDEMA
CLINICAL MANIFESTATIONS OF ANGIOEDEMA
Angioedema refers to abrupt and short-lived swelling
of the skin, mucous membranes, or both including
the upper respiratory and intestinal epithelial linings
(Table 1).1,2,5 Angioedema may be solitary or multi-
ple. It is short lived and fades without visible sequelae
during the course of 24 to 72 hours.
The swelling is non-pitting, erythematous or skin-
colored, and shows a predilection for areas where the
skin is lax rather than taut (especially the face and
genitalia). In the skin, slight heat and pain are vari-
able additional symptoms, but there is rarely itching.
Edema of the respiratory can lead to life-
threatening asphyxia whereas swelling of gastrointes-
tinal tract mucosa can induce violent abdominal pain,
vomiting andor diarrhea. These symptoms occur
mainly in the hereditary form with C1esterase inhibi-
tor (C1-INH) deficiency. Involvement of the respira-
tory tract may be fatal.
Angioedema refers to a group of disorders with
multifactorial etiology but a similar clinical expres-
sion. Several forms of angioedema show a great vari-
ety of tissue localizations, and different underlying
mechanisms such as genetic mutations, allergic reac-
tions and non-allergic reactions exist.
CLASSIFICATIONS OF ANGIOEDEMA IN THE
JAPANESE GUIDELINE
Angioedema is mainly categorized into 3 forms,
namely idiopathic angioedema, extrinsic factor-
induced angioedema, and angioedema with C1-INH
deficiency, in the Japanese guideline (Table 2).1 The
first form is idiopathic angioedema, whose cause is
unknown. The second form included angioedema as-
sociated with allergic and non-allergic reactions due
to various antigens, such as venom, drugs, foods,
pathogens, animals, latex, etc.. The third form is asso-
ciated with C1-INH deficiency and, further, is divided
into two subtypes, namely hereditary angioedema
(HAE) and acquired angioedema (AAE).
Iwamoto et al. reported a nation-wide prevalence
survey of HAE, which was conducted using question-
naires in Japan in 2009 (Fig. 1).1,6 The questionnaires
regarding the numbers, disease types, symptoms and
treatments of angioedema in patients who had visited
hospitals were answered by various departments of
1128 hospitals with 200 or more beds, such as Der-
matology, Otolaryngology, Emergency Medical Care,
Internal Medicine, Pulmonary Medicine, Allergy and
Rheumatology in Japan. In 411 patients of angioe-
Drug-Induced Angioedema
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Fig.　1　National prevalence survey of angioedema in Ja-
pan. HAE, hereditary angioedema; ACE-I, angiotensin-con-
verting enzyme inhibitors. n = 411. Adapted from reference 
6.
Idiopathic
46%ACE-I
8%
Causes/triggers
other than ACE-I
24%
HAE Type I&II
12%
HAE
Type III
AAE
8%
2%
Table　2　Classifi cations of angioedema defi ned in the Japanese guideline
Classifi cation of angioedema Pathophysiology Concurrence of urticaria
I.   Idiopathic angioedma Unknown + or -
II.  Extrinsic factor-induced angioedema Allergic (IgE-mediated) + or -
Non-allergic (Non IgE-mediated)
interference of arachdonic acid metabolism
(aspirin intolerance)
+ or -
kinin-dependent -
others + or -
III. Angioedema due to C1 esterase
inhibitor dysfunction
Kinin-dependent
hereditary
acquired
-
-
Modifi ed from reference 1.
dema reported, 46% patients had idiopathic angioe-
dema, 12% had HAE type I and II, 2% had HAE type
III, 8% had AAE, 8% had ACEI-induced angioedema,
and 24% had angioedema caused and triggered by
causes other than ACEIs.
DRUG-INDUCED ANGIOEDEMA
CLASSIFICATION OF DRUG-INDUCED ANGIO-
EDEMA BASED ON PATHOGENESIS
Drug-induced angioedema is included in the second
form of extrinsic factor-induced angioedema in the
Japanese guideline.
Drug-induced angioedema can be differentiated
into three main categories based on the mechanism;
as these categories are shown in bold letter in Table
3.2,4 Firstly, immediate hypersensitivity reactions to
betalactam antibiotics constitute the most frequent al-
lergic reactions, which are IgE-mediated.7 Other
drugs that can elicit angioedema by the IgE-mediated
mechanism include iodinated contrast media,
neuromuscular blocking agents, pyrazolones, and
quinolones. Secondly, adverse reactions to aspirin
and other NSAIDs represent another important
group with regard to drug-induced angioedema.
NSAID-induced angioedema has been reported to be
a generally non-allergic reaction in which an inhibi-
tion of cyclooxygenase results in major alternations
in arachidonic acid metabolism such as cysteinyl leu-
kotriene overproduction. Although they can also be
responsible for immediate or delayed allergic reac-
tions, e.g. to pyrazolones, in a small subset of pa-
tients, NSAIDs are common elicitors of a non-allergic
reaction, so-called intolerance. Thirdly, the most im-
portant drugs eliciting angioedema apart from
NSAIDs and betalactams are ACEIs. Actually, the
prevalence of angioedema as an adverse reaction due
to ACEIs is not high. However, ACEI-induced angioe-
dema should receive special attention because it
tends to lead to a life-threatening condition accompa-
nied by upper airway obstruction. ACEI-induced an-
gioedema has been reported to be due to an inhibi-
tion of the degradation of bradykinin and such a
mechanism is particular to angioedema, but not to ur-
ticaria. To differentiate a kinin-dependent mechanism
for angioedema, such as ACEI-related angioedema,
from the IgE-mediated mechanism and NSAIDs intol-
erance, it is useful to determine whether angioedema
is accompanied by urticaria or not.
In recent years, as various new drugs have been
approved, the number of drugs that can potentially in-
duce angioedema has increased. Newly approved
drugs have been reported to induce angioedema with
an incidence of more than 1%, including rituximab
(a chimeric monoclonal antibody against the protein
CD20), alteplase (a recombinant tissue plasminogen
activator), fluoxetin (a selective serotonin reuptake
inhibitor), laronidase (a drug for mucopolysacchari-
dosis type I), lepirudin (a recombinant hirudin, an an-
ticoagulant that functions as a direct thrombin inhibi-
tor) and tacrolimus, although their mechanisms have
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Table　3　Classifi cation of drug-induced angioedema based on the pathogenesis
Class Mechanism Representative drugs
Immunologic IgE-mediated Penicillins, Cephalosporins
Immune complex formation and complement activation Penicillins, Therapeutic antisera
Non-immunologic (Pharmacologic) NSAIDs intolerance Aspirin, NSAIDs
Kinin-dependent ACEIs
Direct mast call degranulation Opiates
NSAIDs, non-steroidal anti-infl ammatory drugs; ACEIs, angiotensin-converting enzyme inihibitors.
Modifi ed from reference 2, 4.
Table　4　Drugs associated with angioedema without urticaria
Pharmacological effect Drug Mechanism of angioedema
Angiotensin-converting enzyme inhibitors Captpril, Enarapril, Lisinopril, etc. Inhibition of kinin degradation
Angiotensin II type 1 receptor antagonists 
(Angiotensin II receptor blockers)
Candesartans, Varsartan, 
Losartan,Olmesartan, etc.
Unknown
Nonsteroidal anti-infl ammatory drugs Aspirin, Dicrofenac, Iburofen, etc. Interference with arachidonic acid 
metabolism
Fibrinolytic agents Plasminogen activator, Streptokinase Increased production of bradykinin
Estrogen Combined oral contraceptive pill C1-esterase inhibitor defi ciency?
Modifi ed from reference 9.
never been elucidated.8
DRUG-INDUCED ANGIOEDEMA WITHOUT URTI-
CARIA
Drug-induced angioedema without urticaria may be
caused by an immunoglobulin E-mediated allergic re-
action. However, the pathogenesis remains unclear in
the majority of these reactions. Therefore, since no
immunological mechanism has been identified in
them, skin tests and antibody determinations are typi-
cally unreliable for diagnosing them.
Such patients represent a tough diagnostic and
therapeutic challenge for physicians. Therefore, be-
fore the diagnostic and therapeutic procedure, the co-
existence of urticaria based on the patient history
should be checked.
The causative drugs identified so far that induced
angioedema refractory to antihistamines without urti-
caria are listed in Table 4.9 ACEIs are representative
of the drugs causing this type of angioedema. Zingale
et al. investigated the patients affected by angioe-
dema unaccompanied by urticaria who visited their
hospital over the course of 11 years.10 Among the 776
cases with adequate data, these types of angioedema
were identified: 124 (16%) related to an external agent
such as a drug, insect bite or foodstuff; 85 (11%) re-
lated to treatment with ACEIs; 55 (7%) associated
with an autoimmune disease or infection; and 197
(25%) caused by C1 inhibitor deficiency. In the other
315 cases (41%), the etiology was undiscovered.
Scattered reports describe angioedema without ur-
ticarial as caused by a number of other drugs, such as
metoprolol, calcium channel antagonists, and amio-
dalone for cardiovascular diseases and risperidone
and paroxetine as psychotropic drugs.11-16
NSAID-INDUCED ANGIOEDEMA
ANGIOEDEMA AS A RESULT OF NSAID INTAKE
Stevenson et al. proposed a classification of allergic
and non-allergic reactions induced by NSAIDs that in-
cludes six distinct categories of patients (Table 5).17
Angioedema as a result of NSAID intake is gener-
ally a non-allergic reaction, i.e. so-called “intoler-
ance”, rather than the IgE-mediated, allergic reac-
tions in otherwise healthy patients. However, non-
allergic reactions to NSAIDs resemble superficially
allergic angioedema and are, also, often termed
“pseudoallergic”. The non-allergic reactions have
been considered to develop due to pharmacologic
properties of the drugs.
Other than NSAID-induced angioedema in an oth-
erwise healthy individual, aspirin and other NSAIDs
can also induce or aggregate clinical symptoms in 20-
40% of patients with chronic idiopathic urticariaan-
gioedema.18,19 The exacerbation of wheals by aspirin
in chronic urticaria was more obvious when larger
doses of aspirin were used and at times when wheals
were most active.20
Meanwhile, aspirin asthma is a counterpart of
NSAID-induced urticariaangioedema, but both
rarely co-exist. NSAID intolerance occurs in 2-23% of
patients with asthma.21-23 In our study, 20% of 20 pa-
tients with NSAID-urticaria andor angioedema,
which were diagnosed based on single-blind, placebo-
Drug-Induced Angioedema
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Table　5　Classifi cation of allergic and non-allergic reactions induced by non-steroidal anti-infl ammatory drugs
Type of allergic/non-allergic reactions Suspectedmechanism Underlying disorder
Cross-reaction/
reaction on fi rst 
exposure
1 Asthma and rhinitis exacerbated by NSAID Non-allergic Asthma/sinitis/
polyposis
Yes
2 Urticaria/angioedema exacerbated by NSAID Non-allergic Chronic urticaria Yes
3 Urticaria/angioedema from single NSAID Allergic† None No
4 Acute urticaria/angioedema from multiple NSAIDs Non-allergic None Yes
5 Anaphylaxis from single NSAID Allergic† None No
6 Blended respiratory/cutaneous reaction from one or more NSAIDs Non-allergic
or
Allergic
Asthma/rhinitis/
polyposis
or
None
Yes
or
No
†IgE-mediated. NSAID, non-steroidal anti-infl ammatory drug.
Modifi ed from reference 17.
controlled challenge tests, has history of aspirin
asthma.24 Furthermore, NSAIDs can act as a cofactor
with food allergies to enhance allergic reactions.25
EPIDEMIOLOGY
The prevalence of aspirin and other NSAID intoler-
ance in the average population is 0.3 to 0.9%.26 How-
ever, precise figures for the incidence of aspirin or
other NSAID reactivity in patients presenting with an-
gioedema are not available.
A variety of NSAIDs can cause angioedema. Aspi-
rin and ibuprofen are the most common causes of
such NSAID-induced angioedema.5,27
PATHOPHYSIOLOGY
The proposed mechanism of non-allergic, NSAID-
induced angioedema is one that involves cyclooxyge-
nase (COX) as a common pathway. Non-selective
NSAIDs interfere with arachidonic acid metabolism
through the inhibition of the constitutive COX-1 and
inducible COX-2 pathways with lipoxygenase path-
ways diversion, resulting in overproduction of cystei-
nyl leukotrienes (LT), including LTC4, D4, and E4
(Fig. 2).5 There is also a reduction of the
prostaglandin (PG) E2, which inhibits immunologi-
cally activated rat peritoneal mast cell degranulation
and may have a direct inhibitory effect on cysteinyl
LT production. Thus, the mast cell is presumably the
main cellular target in these reactions.
As this mechanism occurs via a pharmacological
pathway but not via an immunological pathway, many
individuals with NSAID-induced angioedema react to
multiple NSAIDs that are structurally and chemically
unrelated and often on first exposure.
Recent studies suggested that HLA-DRB1*1302
and DQB1*0609, and ALOX5 (encoding 5-lipoxy-
genase) and FcεRIα promoter polymorphisms may
contribute to the pathogenesis of aspirin-related urti-
cariaangioedema.28
CLINICAL FEATURES
The clinical features of NSAID-induced angioedema
do not differ significantly from those of acute allergic
angioedema, and like allergic angioedema, cutaneous
andor mucosal angioedema generally occurs within
minutes to a few hours of ingestion, injection or topi-
cal application of the offending NSAIDs.
DIAGNOSTIC PRINCIPLES
As most patients are aware of their sensitivity to the
relevant drugs, the offending drugs are easily identi-
fied based on the patient’s history. The only reliable
test for NSAID sensitivity is oral challenge, as IgE de-
tections, such as measurements of specific IgE anti-
body and skin tests, cannot identify NSAID intoler-
ance via a non-allergic mechanism. A high proportion
(92%) of patients suspected of aspirin-sensitive urti-
caria andor angioedema, based on history, will be
positive on aspirin challenge.29 The patients with
NSAID-induced angioedema often react to multiple
NSAIDs, whereas in IgE-mediated allergy due to
NSAIDs, the causative drug is usually single (Table
5).19 Although there has been a single report of
aspirin-specific IgE in one asthmatic patient with
aspirin-induced angioedema, IgE anti-salicyloyl anti-
bodies appear to be very rare and there is currently
no in vitro test for them.30 In a provocation test, reac-
tivity to aspirin and other non-selective COX inhibi-
tors can predict multi-responders or single respond-
ers.31
Tests for histamine and LT release after provoca-
tion with NSAIDs are cumbersome, costly, and are
not used routinely. LTC4, D4, and E4 releases have
been demonstrated from basophils and eosinophils of
patients with NSAID intolerance using the cellular an-
tigen stimulation test in specialized centers.32,33
TREATMENT
In case of NSAID-induced angioedema, the emer-
gency measures are basically the same as those for
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Fig.　2　Effect of NSAIDs on arachidonic acid metabolism. ‘Lightening’ symbol indicates inhibition. 
NSAIDs, non-steroidal anti-infl ammatory drugs; COX, cyclooxygenase; PG, prostaglandin; TX, throm-
boxane; LT, leukotriene; 5HPETE, 5 hydroperoxyeicosatetraenoic acid; FLAP, fi ve lipoxygenase acti-
vating factor. Modifi ed from reference 5.
Cell-Membrane Phospholipids
PGG2 5-HPETE
COX
PGH2
PGI2
TXA2
PGF2a
PGE2
PGD2
LTA4
Phospholipases A2
FLAP
5-Lipoxygenase
Peroxydase
Arachidonic acid
LTB4
Elevated microvascular permeability
edema
Degranulation of 
mast cells
LTC4
LTD4
LTE4
NSAIDs
Inhibition
Inhibition
acute allergic angioedema. Patients should be warned
to avoid NSAIDs as a class until safe alternatives can
be confirmed through examinations.
Evidence of the effectiveness of LT receptor an-
tagonist for preventing the exacerbations of angioe-
dema as a result of NSAIDs is not sufficient, although
LT receptor antagonists are theoretically expected to
have an effect on NSAID-induced angioedema.34 Pa-
cor et al. reported that the results of a double-blind,
placebo-controlled study demonstrated that montelu-
kast orally administered once a day is very effective
for the treatment of cutaneous symptoms in patients
with chronic urticaria due to food additives andor as-
pirin.35 However, in some anecdotal cases, the ad-
ministration of LT antagonists concurrently with aspi-
rin or the use of LT antagonist itself provoked ana-
phylactic episodes with urticaria and angioedema.5,36
ALTERNATIVES IN NSAID-INDUCED ANGIO-
EDEMA
Subjects with cross-intolerance are often intolerant to
acetylsalicylic acid and other strong COX-1 inhibitors
and, in some cases, to weak inhibitors such as
meloxicam and paracetamol.24,37,38 Paracetamol (ace-
toaminophen) is generally tolerated, even by patients
sensitive to aspirin, most likely because of very weak
COX-1 inhibition. A classification of the most impor-
tant NSAIDs according to their inhibitory effect on
COX isoenzymes is shown in Table 6.31
The newly introduced selective inhibitors of COX-2
(coxibs) appear to represent safer alternatives in the
patients with NSAID-related urticaria andor angioe-
dema.39 However, the safety of selective COX-2 in-
hibitors is controversial. Some reports have indicated
that 0.2-3% of patients with cutaneous symptoms with
cross-intolerance to NSAIDs are intolerant to COX-2-
selective inhibitors.40-42 In contrast, Dona et al. re-
cently indicated a higher incidence of intolerance to
etoricoxib, as assessed by provocation tests in 252 pa-
tients with urticaria andor angioedema, caused hy-
persensitivity owing to cross-intolerance to NSAIDs.
Twenty-five percent of 47 patients intolerant to
paracetamol and 6% of 205 patients tolerant to
paracetamol were intolerant to etoricoxib. The results
indicated that selective COX-2 inhibitors may be un-
safe in subjects with urticaria andor angioedema
caused by hypersensitivity reactions to NSAIDs with
cross-intolerance if they are intolerant to paraceta-
mol. In addition, intolerance to paracetamol seems to
be a strong predictor for response to COX-2 inhibi-
tors as has been previously suggested by other
authors.43,44
More data from controlled studies are required to
determine the safety of COX2 inhibitors in NSAID-
induced angioedema.
Drug-Induced Angioedema
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Table　6　Classifi cation of the most commonly employed NSAIDs according to the inhibitory effect on COX isoenzymes
Selectivity of inhibitory effect on
COX isoenzymes
NSAIDs
Class Example
COX-1/COX-2 inhibitors Salicylates Aspirin, difl unisal, salsalate
Oxicams Piroxicam
Propionic acid derivatives Ibuprofen, naproxen, loxoprofen†, ketoprofen†, fl urbiprofen†
Arylacetic acids Indomethacin, dicrofenac, etodolac, sulindac, tolmetin
Fenamates Mefenamic acid, meclofenamate
Pyrropyrrole Ketorolac
Pyrazolones Phenylbutazone, oxyphenbutazone, feprazone, noramidopyrine
Weak COX-1/COX-2 inhibitors Paracetamol
(acetoaminophen)
Preferential COX-2 inhibitors Meloxicam, nimeslide
Selective COX-2 inihibitors Coxibs Celecoxib, etoricoxib, rofecoxib
†NSAIDs, which are contained in poultice and application in Japan.
COX, cyclooxygenase; NSAIDs, non-steroidal anti-infl ammatory drugs.
Modifi ed from reference 31.
ACE-INHIBITORS-RELATED ANGIOEDEMA
ACEIs are now widely prescribed for the treatment of
hypertension as well as to provide cardiovascular and
renal protection in patients with heart failure and
chronic kidney disease and those at high risk of car-
diovascular events.45 The issue of adverse effects of
ACEIs is clinically relevant due to the large number
of subjects exposed to these drugs, which is increas-
ing.
Unlike allergic angioedema or NSAIDS-induced an-
gioedema, angioedema as a result of ACEIs is not as-
sociated with urticaria. Moreover, although angioe-
dema may occur during the first week of therapy,
some patients may take the ACEI without any prob-
lem for months or years before angioedema devel-
ops.46,47 Therefore, ACEIs are often overlooked as a
cause of angioedema and this leads to unfortunate
consequences, because continuing administration
tends to lead to more severe attacks.48
However, Grabb et al. found that in more than 50%
of the cases of ACE-related angioedema, ACEI ther-
apy has been continued.49 Accordingly, Agostoni et
al. indicated that in ACEI-associated angioedema,
ACEIs may facilitate angioedema in predisposed indi-
viduals rather than cause angioedema independ-
ently.31
EPIDEMIOLOGY
Angioedema occurs in 0.1 to 0.7% of patients taking
ACEIs, and it can affect approximately 1 of 2500 pa-
tients during the first week of exposure.48,50 Although
the reported incidence of ACEI-associated angioe-
dema is not very high, it represents the most fre-
quent causes of recurrent drug-induced angioedema.9
The mortality worldwide is 0.1% in these cases.
Considering that, at present, 40 million patients
worldwide are treated with ACE inhibitor, this drug
class could account for several hundred deaths per
year due to laryngeal edema according to the report
by Messerli et al. in 2000.51
Various risk factors for ACEI-related angioedema
have been indicated, including black race, female
gender, past history of angioedema such as HAE, pre-
vious drug rash, smoking habit, age older than 65
years, seasonal allergies, recent initiation of ACEIs
(first week of therapy), obesity, upper airway surgery
or trauma, sleep apnea and immunosuppression in
cardiac and renal transplant recipients.52-54
CLINICAL FEATURES
The manifestations of ACEI-related angioedema are
similar to those observed in patients with C1INH defi-
ciency. In ACEI-related angioedema, however, edema
is more frequently localized to the head and neck,
such as the face, mouth mucosa, tongue, lips, phar-
ynx and larynx, while the occurrence of painful intes-
tinal andor genital edema is a more rare manifesta-
tion than HAE.55 Reports indicating the existence of a
partial defect of C1INH have been confirmed.56
Therefore, the co-existence of C1INH deficiency
should be differentiated in the diagnostic work-up.
Unlike in other cases of drug-induced angioedema,
adverse reactions to ACEIs are frequently missed be-
cause of the irregular clinical course. Actually, physi-
cians expect angioedema, generally allergic or non-
allergic in nature, to occur in close temporal relation-
ship to the time that the causative drug is taken. How-
ever, ACE-related angioedema can not only start
years after the treatment is begun, but it recurs ir-
regularly while the patient is under that treatment.
Additionally, some cases of late onset of angioedema
have also been observed weeks after the discontinu-
ation of the ACEIs.9 In ACEI-related angioedema, the
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Fig.　3　Mechanism of bradykinin-mediated angioedema as a result of therapy with inhibitors of the renin-
angiotensin-aldosterone system. ‘Lightening’ symbol indicates inhibition. ACE, angiotensin converting en-
zyme; AT1, angiotensin II type-1; AT2, angiotensin II type-2; ARBs, angiotensin receptor blockers; HMW, 
high molecular weight; LMW, low molecular weight. Modifi ed from reference 59.
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interval between the first intake of ACEIs and the on-
set of angioedema varies from a few hours to 8 years.
Sixty percent of the Japanese cases experienced the
first angioedema in a week after starting the admini-
stration of ACEIs.47 A Japanese case with severe an-
gioedema after the first intake of ACEIs has been re-
ported.57 When angioedema involved the face and
viscera, it developed within the first week in 60%
and 59% of cases, respectively.46 Furthermore, life-
threatening edema of the upper airway is present in
up to approximately 40% of cases and can be resistant
to treatment or even fatal.46,58
PATHOPHYSIOLOGY
The pathogenetic mechanism appears to be mainly
linked to the decreased degradation of bradykinin,
which potentially dilates blood vessels, mediates in-
flammation, increases vascular permerability and acti-
vate nociceptors.
ACE, also known as kininase II, doses not just act
on angiotensin I, but it is also a major inactivator of
bradykinin (Fig. 3).59 Pharmacological inhibition of
ACE leads to increased levels of bradykinin. Actually,
high levels of bradykinin have been demonstrated in
plasma during an acute episode of angioedema.60
Bradykinin degradation is blocked in all patients
treated with ACEIs. Nevertheless, angioedema ap-
pears inconstantly and in just a small percentage of
such patients. Therefore, it is likely that factors other
than impaired bradykinin degradation by ACE are in-
volved in the development of angioedema.
In contrast with what happens in HAE, no cleaved
high molecular weight kininogen, a precursor of
bradykinin, was detectable in plasma.56 This finding
supports the hypothesis that the pathogenetic mecha-
nism of ACEI-related angioedema lies in the catabolic
site of bradykinin metabolism. Therefore, studies
which aimed to identify the factors predisposing pa-
tients to ACEI-induced angioedema focused their at-
tention on the discovery of abnormalities in enzymes
involved in bradykinin catabolism.
Bradykinin is degraded primarily by ACE (Fig.
4).61 However, during ACE inhibition, other en-
zymes, including neutral endopeptidase (NEP-24.11),
aminopeptidase P (APP), and kininase I (carboxypep-
tidase N), are presumed to play greater role in the
metabolism of bradykinin.
In a large cohort of patients with ACEI-related an-
gioedema, the mean plasma levels of kininase I were
slightly reduced compared with those in patients who
did not develop adverse effects.62 However, the large
overlap of kininase I levels between the 2 groups lim-
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Fig.　4　The schema of the degradation of bradykinin and substance P. HMWK, high molecular weight kinino-
gen; APN, APN or aminopeptidase M; NEP, neutral endopeptidase; DPPIV, dipeptidyl peptidase IV; APP, 
aminopeptidase P; ACE, angiotensin-converting enzyme. Dashed line shows cleavage of an inactive bradyki-
nin fragment. Modifi ed from reference 61.
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its the value of kininase I measurement to predict the
risk of ACE-related angioedema.
Cleavage of bradykinin by kininase I yields the ac-
tive metabolite des-Arg9-bradykinin, which is inacti-
vated primarily by APP. According to a report by
Blais et al., nearly half of the patients with ACEI-
related angioedema have a defect in a serum enzyme
which involves the des-Arg bradykinin metabolism,
leading to its accumulation.63
Byrd JB et al. indicated that decreased APP activity
and dipeptidyl peptidase IV (DPPIV or CD26) in the
substance P degradation pathways may also play a
role in ACEI-associated angioedema.61 ACE also de-
grades substance P, which produce tracheal edema
in animals, as well as bradykinin. Bradykinin stimu-
lates the release from sensory nerves of substance P,
which causes increased vascular permeability by act-
ing at the NK1 receptor, in addition to increasing vas-
cular permeability directly via its B2 receptor.64 In the
setting of ACE inhibition, DPPIV, however, sequen-
tially degrades substance P to substance P 5-11,
which is susceptible to further degradation by
aminopeptidase N (APN or CD13).65
Recently, a polymorphism of XPNPEP2 (the -2399
A variant), a candidate gene encoding membrane-
bound APP, is associated with reduced APP activity
and a higher incidence of ACEI-related angioe-
dema.66 Whereas the gene encoding for membrane-
bound APP, the source of circulating APP activity, is
X linked, ACEI-related angioedema is thought to be
more common in women than in men.66,67
Taken together, these findings suggest that in-
creased plasma bradykinin levels play a key role in
the course of ACEI-related angioedema, but addi-
tional factors are probably involved in the underlying
pathophysiological pathways.
DIAGNOSTIC PRINCIPLES
The diagnosis of ACEI-related angioedema should be
preceded by the exclusion of other pathologies such
as allergic and non-allergic reactions due to antigens,
such as foods and venoms, C1INH deficiency, and in-
fection. Furthermore, it is important to keep in mind
that patients taking ACEIs can develop angioedema
even after many years of uneventful ACEI treatment,
as no reliable tests can differentiate ACEI-related an-
gioedema from angioedema due to other causes.
TREATMENT
Following basic emergency treatment, it is important
to discontinue any drugs suspected to induce angioe-
dema. Furthermore, anti-allergic drugs and anti-
inflammatory drugs, such as glucocorticoids, are
often used, although current evidence suggests that
such therapy is rather ineffective in ACEI-related an-
gioedema.68,69 Thus, symptom-related medical care
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should be provided until the swellings are dissolved.
The swellings will normally subside in approximately
72 hours with or without treatment. In 1993,
Thompson T, an otolaryngologist, reported that in 36
patients with angioedema due to ACEIs who visited
his hospital in the U.S., 2 patients were intubated, 1
had the placement of a nasal trumpet, which is a na-
sopharyngeal airway designed to be inserted into the
nasal passageway to secure an open airway, and 3 re-
quired tracheostomies, although 30 patients were
successfully managed with medical therapy.70 The
author emphasized that the recognition that angioe-
dema resulting from ACEIs is probably not IgE medi-
ated and that antihistamines and steroids may not al-
leviate the airway obstruction is highly necessary for
the treatment of ACEI-related angioedema.
Weber et al. recently proposed the introduction of
a bradykinin inhibitor, icatibant, as a new treatment
for ACEI-associated angioedema. They indicated that
since bradykinin is a major mediator of angioedema
from ACEIs, icatibant, presently used in patients with
HAE, could be effective for these patients.45 New ap-
proaches targeting the kalliklein-kinin system, such
as kalliklein inhibitors and bradykinin type-2 receptor
antagonists, might improve treatment for ACEI-
induced angioedema in the near future.
ALTERNATIVES IN ACEI-RELATED ANGIO-
EDEMA
Safe alternatives should be recommended for patients
with ACE-related angioedema to manage hyperten-
sion.
Various ACEIs, including enalapril, lisinopril, cap-
topril, ramipril, imidapril, benazepril, trandolapril and
perindopril, are in use in many countries. Since an-
gioedema is, however, a drug class effect, it is very
important that physicians consider these drugs in the
differential diagnosis of angioedema and give proper
advice to these patients on avoiding all ACEIs.
Angiotensin-II type-1 receptor antagonists, also
known as angiotensin receptor blockers (ARBs) or
AT1-blockers, have been thought to be relatively safe
alternatives for patients with previous history of
ACEI-associated angioedema, because ARBs block
the angiotensin II at the receptor levels and, theoreti-
cally, have no direct effect on the inhibition of
bradykinin breakdown. In the literature, although the
incidence of angioedema in patients receiving ARBs
has rarely reported, it is estimated to be lower than in
patients receiving ACEIs. An overall incidence of 0.3%
(n = 25 of 8576) angioedema was reported for ACEIs,
whereas the use of ARBs was associated with a much
lower risk of angioedema (0.1%; n = 10 of 8542 pa-
tients) during the ONTARGET study.71
According to Malde et al., only 8% of patients who
experienced angioedema due to ACEIs previously de-
veloped angioedema with ARBs.72 Actually, various
ARBs have recently been shown to increase serum
bradykinin levels, probably via the angiotensin-II acti-
vation of angiotensin-II type-2 (AT2) receptors and
the subsequent inhibition of bradykinin breakdown
(Fig. 4).73,74 Thus, for practical purposes, ARBs
should not be considered an ideal alternative for
ACEI treatment.75 Although the incidence of angioe-
dema induced by AT1-blockers is lower than that for
angioedema related by ACEIs, patients who devel-
oped ACEI-related angioedema are more likely to be
susceptible to angioedema due to AT1 blockers than
individuals of general populations.76,77 However, rare
entities like calcium channel blocker-associated small
bowel angioedema may have an impact on therapeu-
tic decision-making in hypertensive patients as well.
The first oral direct renin inhibitor, aliskiren, re-
ceived Food and Drug Administration approval for
the treatment of hypertension in 2007 and, in Japan,
was also approved in 2009. A more complete renin-
angiotensin system inhibition than that obtained with
existing agents is produced by the novel mechanism
of action of aliskiren, namely the inhibition of renin’s
catalytic activity. As direct renin inhibition should not
alter local or circulating bradykinin, aliskiren may be
an alternative in patients with ACEI and ARB-related
angioedema.78 However, a recent pharmacovigilance
analysis showed angioedema and renal dysfunction to
be potential adverse reactions associated with al-
iskiren.79
Accordingly, ARBs and renin inhibitors should be
used with caution in patients who previously reacted
with angioedema to ACEIs, and only if there are no
other alternative satisfactory treatments, until more
information from larger studies becomes available.
DIAGNOSTICS OF DRUG-INDUCED ANGIO-
EDEMA
Firstly, a thorough patient history is indispensable,
particularly in determining the frequency of occur-
rence, previous angioedema with or without the same
family history, known allergies and other diseases,
medications and possible triggering cofactors such as
physical exercise, alcohol, NSAID intake and infec-
tions.
Secondly, a general predisposition to recurrent
anaphylaxis due to mastocytosis and a congenital pre-
disposition to angioedema due to complement defi-
ciency have to be excluded.
Finally, previous unknown food hypersensitivity
should be ruled out. Recently, patients with wheat-
dependent, exercise-induced anaphylaxis after sensi-
tization to hydrolyzed wheat proteins (HWPs)
through the skin and mucosa when using a soap con-
taining HWPs, have increased dramatically in Ja-
pan.80,81 The major clinical manifestation of wheat al-
lergy via cutaneous andor mucosal sensitization to
HWPs is swelling of the face, especially the eyelids.
As food allergy in adulthood is often enhanced by co-
factors, such as exercise and NSAIDs intake, in the
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case of sporadic recurrent angioedema, the relevant
cause should be identified among foods, drugs, and
exercise by means of examinations.82
After physical examination, to exclude possible
eliciting factors and predisposition factors, tests, such
as C1-INH, C4, and C1q for HAE, should be consid-
ered according to the patient history. In cases of sus-
pected drug-induced angioedema, specific allergy
tests must be performed, including skin tests, such as
skin prick tests and intradermal tests, as well as in vi-
tro determination of specific IgEs, basophil activation
test, and lymphocyte transformation tests, if neces-
sary. These tests are often necessary to differentiate
allergic and non-allergic mechanisms of relevant
drugs, even though in angioedema due to NSAID in-
tolerance and kinin-dependent angioedema these
tests tend to show negative results. Finally, provoca-
tion tests may be performed in cases with non-life-
threatening reactions to determine tolerated alterna-
tive drugs.
PREVENTING DRUG-INDUCED ANGIO-
EDEMA
The first criterion for prevention relies on taking the
patient’s history. As a general rule, patients with a
previous history call for particular attention. Thus, es-
trogen and ACE inhibitors should be avoided in pa-
tients with hereditary and acquired C1-INH defi-
ciency. In addition, ACEIs should be avoided in pa-
tients who have experienced idiopathic angioedema,
if possible. In these patients, caution should also be
used when fibrinolytic agents or ARBs are needed.
As not enough data to draw conclusions about par-
ticular means of prevention in patients with some an-
gioedema has been collected, further surveillance is
needed.
In the case of ACEI-related angioedema, it should
be emphasized that angioedema has to be considered
a class effect and that no attempt to switch to another
compound of the same class should be made in pa-
tients developing angioedema. As the predictive fac-
tors for developing ACEI-related angioedema have
not been identified yet, all patients who are pre-
scribed ACEIs, should be made aware of the possibil-
ity of this adverse reaction.
CONCLUSIONS
Drug-induced angioedema can be elicited by several
main pathophysiological mechanisms, namely IgE-
mediated allergic reactions, aspirin and other NSAID
intolerance, e.g. due to pharmacological inhibition of
cyclooxygenase, and bradykinin-related reactions.
The main point emerging from the recent reports is
that ACEI-related angioedema prominently differs
from the allergic reactions and NSAID intolerance
with regard to the clinical manifestations. Unlike in
other cases of drug-induced angioedema, ACEI-
related angioedema is frequently missed as it may de-
velop several hours or long after the drug is started
and may disappear without discontinuation of the
causative ACEIs.
Currently, not enough data on drug-induced an-
gioedema have been accumulated to prevent and
manage the condition. No treatment effective for
kinin-dependent angioedema due to drugs has been
established, in contrast to allergic angioedema due to
drugs. In tandem with the introduction of various
new drugs to the market, trends in drug-induced an-
gioedema can change. Accordingly, it is necessary to
monitor instances of angioedema occurring with any
drug in order to obtain significant data and identify
the predisposition factors for drug-induced angioe-
dema. Furthermore, it is important to share the col-
lected data regarding drug-induced angioedema with
physicians in a timely way in order to diagnose and
manage drug-induced angioedema appropriately.
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